Hikal

With reference to the news article appearing in a leading daily titled "Pfizer gets relief on epilepsy drug as US court reverses ruling", Hikal Ltd has clarified that it is neither in the finished formulation business nor does it market finished dosage forms in the US. In addition the Company has consulted its attorneys who have confirmed that the Company has a sound patent situation. Initial communication with its customers indicate that there would be no interruptions for the supply of Gabapentin from the Company and that they are not affected by the recent judgement of the US courts. The Company expect it to be business as usual for the Company and its supply of Gabapentin.